Medpace is pleased to announce the addition of three scientists to our Central Laboratory leadership team.
Read More
In a recent article published in Clinical Leader, Ed Miseta, Chief Editor highlights Medpace’s partnership with Locus Biosciences and their development of crPhage™, a bacteriophage that have been engineered to deliver the CRISPR-Cas3 constructs into the target bacteria.
Read More
As part of our efforts to expand laboratory services and capabilities, specifically in Asia, Medpace has relocated our central laboratory facilities from Beijing to Shanghai. The Shanghai lab is a larger laboratory (with a 180% increase in space) and has allowed Medpace to expand capabilities to better service our client’s clinical trials in China.
Read More
We sat down with Christopher Daniels, Director, Clinical Laboratory Services at Medpace, to discuss regulations and standards for biomarkers, validation process for central labs, and the benefit of working with an experienced partner.
Read More
Medpace is committed to keeping Sponsors on PACE to maintain regular activity during this irregular time.
Read More
In a process-oriented industry that breathes deeply from a standard set of regulations, it is easy to see the importance of each storage unit in the repository and the value of a biorepository risk mitigation plan.
Read More
To serve our Sponsors in their COVID-19 programs, Medpace has expedited COVID-19 assay validations to meet clinical trial testing standards.
Read More
As part of our efforts to expand laboratory services and capabilities, Medpace’s central lab in Belgium recently completed extensive expansions including a new modern laboratory building at the Leuven facility. Highlights include an expanded onsite PhD Team, new molecular suite, flow cytometry services grow, biorepository updates, and logistics/kit building expansion
Read More
Dr. El Mustapha Bahassi, Associate Director of Clinical Laboratories at Medpace, highlights the biomarker landscape in immuno-oncology clinical research.
Read More
Experts from Medpace’s central laboratory evaluated the effect of hemolysis, icterus and lipemia on chemistry assays and assessed the association between the amount of interfering substances and ordinal values reported by the automated chemistry analyzer as H-, I- and L-indices. They presented their findings at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago.
Read More